GSK (LON:GSK) Price Target Raised to GBX 2,100

GSK (LON:GSK) had its target price upped by Jefferies Financial Group from GBX 2,000 to GBX 2,100 in a research report report published on Monday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

GSK has been the subject of several other research reports. Shore Capital restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a report on Monday, October 20th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Thursday, October 23rd. Berenberg Bank restated a “hold” rating and issued a GBX 1,600 target price on shares of GSK in a report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,450 price target on shares of GSK in a research report on Thursday, July 31st. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, GSK currently has an average rating of “Hold” and an average price target of GBX 1,730.

GSK Trading Up 0.1%

Shares of GSK stock opened at GBX 1,790.92 on Monday. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,799. The business’s fifty day moving average is GBX 1,578.08 and its two-hundred day moving average is GBX 1,478.86. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm has a market cap of £71.98 billion, a PE ratio of 13.47, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling

In other GSK news, insider Wendy Becker purchased 526 shares of GSK stock in a transaction on Friday, September 19th. The shares were purchased at an average cost of GBX 1,503 per share, with a total value of £7,905.78. Insiders have purchased a total of 576 shares of company stock valued at $865,799 in the last 90 days. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.